WIRE - Novel Treatments in Renal Cell Cancer

NCT03741426 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Cancer

Interventions

DRUG: Olaparib
DRUG: Cediranib
DRUG: Durvalumab

Sponsor

CCTU- Cancer Theme

Collaborators

[object Object]
[object Object]
[object Object]